Unassociated Document
Filed
Pursuant to Rule 424(b)(5)
Registration
No. 333-161315
and Registration
No. 333-165356
PROSPECTUS
SUPPLEMENT
(To
Prospectus dated September 16, 2009)
2,231,818
shares of Common Stock
We are
offering up to 2,231,818 shares of our common stock at a public offering price
of $5.50 per share. Our common stock is traded on the Nasdaq Global
Market under the symbol “ACFN.” On March 8, 2010, the closing price
of our common stock on the Nasdaq Global Market was $6.75 per
share.
We are
offering these shares on a best efforts basis. We have retained Merriman Curhan
Ford & Co. to act as our exclusive placement agent in this offering, and we
will pay fees to it in connection with this offering equal to 6.0% of the
proceeds of the offering, except for shares sold to certain
investors. We have also agreed to reimburse the placement agent for
certain expenses incurred by it in connection with the offering. In
no event will the fees and expense reimbursements received by the placement
agent exceed an aggregate of 8.0% of the gross proceeds of the offering. The
placement agent is not required to purchase or sell any of the shares offered by
this offering, but will use its commercially reasonable efforts to sell the
shares offered. Because there is no minimum offering amount required
as a condition to closing in this offering, the actual public offering amount,
placement agent’s fee and net proceeds to us, if any, in this offering are not
presently determinable and may be substantially less than the maximum offering
amounts set forth below.
Investing in our securities
involves a high degree of risk. See “Risk Factors” beginning on page
S-4 of this prospectus supplement.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
|
|
Per
Share
|
|
|
Total
|
|
Public
offering price
|
|
$
|
5.50
|
|
|
$
|
12,274,999
|
|
Placement
agent’s fee (1)
|
|
$
|
0.33
|
|
|
$
|
736,500
|
|
Proceeds
to Acorn Energy, Inc. (before expenses)
|
|
$
|
5.17
|
|
|
$
|
11,538,499
|
|
(1)
|
Assumes
all of the shares offered hereby are sold and that the placement agent
receives a fee for all of the shares sold. See the section
entitled “Plan of Distribution” for a full description of the compensation
to be paid to the placement agent.
|
We
estimate the total expenses of this offering, excluding the placement agent’s
fee, will be approximately $240,000.
Delivery
of the shares to purchasers will be made on or about March 11,
2010.
As
Placement Agent
March
8, 2010
This
prospectus supplement and the accompanying base prospectus, dated September 16,
2009, relate to the offer by us of 2,231,818 shares of our common stock. You
should rely only on the information contained in this prospectus supplement, the
accompanying base prospectus and the documents incorporated by reference herein
or therein. We have not authorized any other person to provide you with
different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. You
should assume that the information contained in this prospectus supplement and
the accompanying base prospectus is accurate only as of their respective dates,
regardless of the time of delivery of this prospectus supplement and
accompanying base prospectus or of any sale of shares. Our business, financial
condition, results of operations and prospects may have changed after the date
of this prospectus supplement. You should not consider this prospectus
supplement or the accompanying base prospectus to be an offer or solicitation
relating to the securities in any jurisdiction in which such an offer or
solicitation relating to the securities is not authorized. Furthermore, you
should not consider this prospectus supplement or the accompanying base
prospectus to be an offer or solicitation relating to the securities if the
person making the offer or solicitation is not qualified to do so, or if it is
unlawful for you to receive such an offer or solicitation.
________________
TABLE
OF CONTENTS
Prospectus
Supplement Dated March 8, 2010
ABOUT
THIS PROSPECTUS SUPPLEMENT
|
S-1
|
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
S-1
|
PROSPECTUS
SUPPLEMENT SUMMARY
|
S-2
|
THE
OFFERING
|
S-3
|
RISK
FACTORS
|
S-4
|
USE
OF PROCEEDS
|
S-5
|
DILUTION
|
S-6
|
PLAN
OF DISTRIBUTION
|
S-7
|
LEGAL
MATTERS
|
S-8
|
EXPERTS
|
S-8
|
WHERE
YOU CAN FIND MORE INFORMATION
|
S-8
|
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
|
S-8
|
Base
Prospectus dated September 16, 2009
ABOUT
THIS PROSPECTUS
|
1
|
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
1
|
ABOUT
ACORN ENERGY
|
2
|
RISK
FACTORS
|
3
|
USE
OF PROCEEDS
|
3
|
SECURITIES
WE MAY OFFER
|
3
|
DESCRIPTION
OF CAPITAL STOCK
|
4
|
DESCRIPTION
OF DEBT SECURITIES
|
5
|
DESCRIPTION
OF WARRANTS
|
11
|
DESCRIPTION
OF RIGHTS
|
13
|
DESCRIPTION
OF UNITS
|
13
|
PLAN
OF DISTRIBUTION
|
13
|
LEGAL
MATTERS
|
16
|
EXPERTS
|
16
|
WHERE
YOU CAN FIND MORE INFORMATION
|
16
|
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
|
16
|
ABOUT
THIS PROSPECTUS SUPPLEMENT
You
should carefully read this entire prospectus supplement and the accompanying
base prospectus, including the information included and referred to under “Risk
Factors” below, the information incorporated by reference in this
prospectus supplement and in the accompanying base prospectus and the financial
statements and the other information incorporated by reference in the
accompanying base prospectus, before making an investment decision.
This
prospectus supplement and the accompanying base prospectus are part of a
registration statement on Form S−3 that we filed with the Securities and
Exchange Commission, or SEC, using a “shelf” registration process. Under this
shelf registration process, we may offer and sell any combination of securities
described in the accompanying base prospectus in one or more offerings, up to a
total dollar amount of $12,275,000. The accompanying base prospectus provides
you with a general description of the securities we may offer. Each time we use
the accompanying base prospectus to offer securities, we will provide a
prospectus supplement (such as this prospectus supplement) that will contain
specific information about the terms of that offering. This prospectus
supplement, the accompanying base prospectus and the documents incorporated by
reference herein and therein include important information about us, the
securities we are offering and placement arrangements of the offering and other
information you should know before investing.
To
the extent that any statement that we make in this prospectus supplement is
inconsistent with statements made in the accompanying base prospectus, the
statements made in this prospectus supplement modify or supersede those made in
the accompanying base prospectus. You should read both this prospectus
supplement and the accompanying base prospectus together with additional
information described under the heading, “Where You Can Find More Information,”
which are collectively referred to herein as “this prospectus.”
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus supplement, the base prospectus and the registration statement of
which it forms a part and the documents incorporated by reference into these
documents contain forward-looking statements within the meaning of Section 27A
of the Securities Act, and Section 21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. We use words such as “anticipates,” “believes,”
“plans,” “expects,” “future,” “intends,” “will,” “foresee” and similar
expressions to identify these forward-looking statements. These forward-looking
statements are subject to certain known and unknown risks and uncertainties, as
well as assumptions that could cause actual results to differ materially from
those reflected in these forward-looking statements. Factors that might cause
actual results to differ include, but are not limited to, those set forth and
referenced in the section entitled “Risk Factors” beginning on page S-4 of
this prospectus supplement. Readers are cautioned not to place undue
reliance on any forward-looking statements contained herein, which reflect
management’s opinions only as of the date hereof. Except as required by law, we
undertake no obligation to revise or publicly release the results of any
revision to any forward-looking statements. You are advised, however, to consult
any additional disclosures we have made or will make in our reports to the SEC
on Forms 10-K, 10-Q and 8-K. All subsequent written and oral forward-looking
statements attributable to us or persons acting on our behalf are expressly
qualified in their entirety by the cautionary statements contained in this
prospectus supplement and the base prospectus.
PROSPECTUS
SUPPLEMENT SUMMARY
This summary description highlights
selected information
contained elsewhere in this prospectus supplement or incorporated herein
by reference. This
summary may not contain all of the information that you should consider before buying securities in
this offering. You should carefully read this entire prospectus supplement
and the base prospectus, including each of the
documents incorporated herein or therein by reference, before making an
investment decision. As used herein, “we,” “us,” and “our” refer to Acorn Energy and
its subsidiaries.
Our
Company
Acorn
Energy is a holding company focused on improving the efficiency and
environmental impact of the energy infrastructure, fossil fuel and nuclear
industries. Our operating companies are focused on three problems in the energy
sector: improving the efficiency of the energy grid; reducing the risk for
owners of large energy assets; and reducing the environmental impact of the
energy sector. Our companies leverage advanced technologies to transform the
existing energy infrastructure. We aim to acquire primarily controlling
positions in companies led by promising entrepreneurs and we add value by
supporting those companies with financing, branding, positioning, and strategy
and business development.
Through
our majority-owned operating subsidiaries and a company in which we own a
significant equity interest we provide the following services:
· SCR Catalyst and Management Services.
We provide selective catalytic reduction, or SCR, management and catalyst
regeneration services for coal-fired power plants through our CoaLogix
subsidiary. These services include SCR catalyst management, cleaning
and regeneration as well as consulting services to help power plant operators to
optimize efficiency and reduce overall nitrogen oxide compliance
costs.
· Naval and RT
Solutions. We provide sonar and acoustic related solutions for
energy, defense and commercial markets with a focus on underwater site security
for strategic energy installations and other real-time and embedded hardware and
software development and production through our DSIT subsidiary.
· Energy Infrastructure Software (EIS)
Services. We provide energy infrastructure software services through our
Coreworx Inc. subsidiary. Coreworx is a leading provider of integrated project
collaboration and advanced document management solutions for the architecture,
engineering and construction markets, particularly for large capital projects in
the energy industry.
· GridSense Pty Ltd., in which
we own a significant equity interest, provides remote monitoring and control
systems to electric utilities and industrial facilities worldwide.
Our
Corporate Information
Our
executive offices are located at 4 West Rockland Road, Montchanin, Delaware
19710, our telephone number at that location is (302) 656-1707, and our website
can be accessed at www.acornenergy.com. Information contained in our
website does not constitute part of this prospectus supplement or the base
prospectus.
THE
OFFERING
Common
stock offered by us
|
2,231,818
shares
|
Common
stock outstanding before this offering (1)
|
11,987,330
shares
|
Common
stock to be outstanding after this offering (assuming sale of all
2,181,818 offered shares)
|
14,219,148
shares
|
Use
of proceeds
|
We
intend to use the net proceeds received from the sale of the shares to
finance in part certain pending acquisitions, for possible future
acquisitions and for working capital and other general corporate purposes.
See “Use of Proceeds” on page S-5.
|
Risk
factors
|
See
“Risk Factors” included and referred to on page
S-4
for a discussion of factors you should carefully consider before deciding
to invest in our common stock.
|
Nasdaq
Global Market symbol
|
ACFN
|
(1) Does
not include: 233,306 warrants outstanding, all of which are exercisable at a
price of $4.50, and 1,421,831 options outstanding and
exercisable with a weighted average exercise price of $3.52 per share, which
warrants and options, if exercised, would result in the issuance of an
additional 1,655,137 shares of our common stock; and 323,334 options that are
outstanding, but have not yet vested. Also does not include
approximately1,590,000
shares expected to be issued in connection with pending acquisition
transactions.
RISK
FACTORS
An investment in our common stock
involves a high degree of risk. Before making an investment decision you should
carefully consider the risks described below and the risks and uncertainties
described in our other periodic filings, including Part II, Item 1A of our
Annual Report on Form 10-K for the year ended December 31, 2008, which is
incorporated by reference herein, and the other information set forth or
incorporated by reference in this prospectus supplement and the accompanying
base prospectus. The risks and uncertainties described or incorporated by
reference in this prospectus supplement and the
accompanying prospectus are not the only ones we face. Additional
risks and uncertainties that we are unaware of or that we believe are not
material at this time could also materially adversely affect our business,
financial condition or results of operations. You should also refer to our
financial statements and the notes to those statements, which are incorporated
by reference in this prospectus supplement.
Our
use of the offering proceeds may not yield a favorable return on your
investment.
We
currently intend to use the net proceeds received from the sale of the
securities to finance in part certain pending acquisitions, to
finance possible future acquisitions and for working capital and other general
corporate purposes. Our management has broad discretion over how these proceeds
are used and could spend the proceeds in ways with which you may not agree.
Pending the use of the proceeds in this offering, we will invest them. However,
the proceeds may not be invested in a manner that yields any significant
return.
As
a new investor, you will incur substantial dilution from the price paid in this
offering.
The
offering price is substantially higher than the net tangible book value per
share of our outstanding common stock. As a result, based on our capitalization
as of September 30, 2009, investors purchasing common stock in this offering
will incur immediate dilution of $3.18 per share of common stock purchased,
based on the offering price of $5.50 per share. Such investors may
experience additional dilution upon the exercise of outstanding stock options
and warrants having exercise prices less than the per share offering price to
the public in this offering. See “Dilution” on page S-6.
Our share price may decline due to
the large number of shares
of our common stock eligible for future sale in the
public market including shares underlying warrants and
options.
A substantial number of shares of our
Common Stock are or could become eligible for sale in the public
market as described below. Sales of a substantial number of shares of
our common stock in the public market, or the
possibility of these sales, may adversely affect our stock
price.
As of the date hereof, 11,987,330 shares
of our common stock are issued and outstanding. We have 233,306 warrants
outstanding and exercisable, all of which have an exercise price of $4.50, and
1,421,831 options outstanding and exercisable with a weighted average exercise
price of $3.52 per share, which if exercised would result in the issuance of an
additional 1,655,137 shares of our common stock. An additional 323,334 options are
outstanding, but have not yet vested.
Substantially all our outstanding shares
and shares issuable under our outstanding options and warrants are or would be
freely tradable.
In addition to the 2,231,818 shares
being offered in this offering, we will be issuing approximately 1,590,000
additional shares in connection with certain previously announced pending
acquisition transactions, if and when they are consummated, of which 660,000
will be freely tradable upon issuance, 735,000 will be freely tradable within
six months of their issuance and the balance will be freely tradable one year
after their issuance.
USE
OF PROCEEDS
We
estimate that the net proceeds of this offering, after deducting placement agent
fees and our estimated offering expenses, will be approximately $11.3 million,
assuming all the shares offered hereby are sold and that the placement agent
receives a fee for all of the shares sold.
We expect
to use a portion of the net proceeds from this offering for the
following: $2.9 million to fund our CoaLogix subsidiary; up to $3.5
million if we exercise all of our remaining options to acquire shares of US
Sensor Systems, Inc.; $1.5 million to complete our acquisition of GridSense; and
$2.0 million that we have committed to GridSense after
acquisition. We plan to use the balance of the proceeds for general
corporate purposes and/or to finance future acquisitions.
Our
management has broad discretion as to the allocation of the net proceeds
received in this offering and may use these proceeds for those purposes in the
future.
DILUTION
If you
invest in our shares, your interest in the common stock contained therein will
be diluted to the extent of the difference between the public offering price per
share of our shares and the net tangible book value per share of our common
stock after this offering. Our net tangible book value on September
30, 2009 was approximately $19,843,000, or approximately $1.77 per share of
common stock. Net tangible book value per share is determined by
dividing our net tangible book value, which consists of tangible assets less
total liabilities, by the number of shares of common stock outstanding on that
date. Dilution in net tangible book value per share represents the
difference between the amount per share paid by purchasers of shares in this
offering and the net tangible book value per share of common stock immediately
after the completion of this offering. Without taking into account
any other changes in our net tangible book value after September 30, 2009, other
than to give effect to our receipt of the estimated proceeds from the sale of
the maximum number of shares issuable in this offering (2,231,818 shares) at a
public offering price of $5.50 per share, less the fees due to the placement
agent and our estimated offering expenses, our pro forma net tangible book value
as of September 30, 2009, after giving effect to the items above, would have
been approximately $31,141,000, or $2.32 per share. This represents an immediate
increase in the net tangible book value of $0.55 per share to existing
stockholders and an immediate dilution of $3.18 per share to anyone who
purchases shares in the offering. The following table illustrates this per share
dilution:
Public
offering price per share:
|
|
|
|
|
$ |
$5.50 |
|
Net
tangible book value per share as of September 30, 2009
|
|
$ |
1.77 |
|
|
|
|
|
Increase
in net tangible book value per share attributable to this
offering:
|
|
$ |
0.55 |
|
|
|
|
|
Pro
forma net tangible book value per share as of September 30, 2009 after
giving effect to this offering:
|
|
|
|
|
|
$ |
2.32 |
|
Dilution
per share to new investors in this offering:
|
|
|
|
|
|
$ |
3.18 |
|
The
foregoing table is based 11,210,005 shares of our common stock outstanding as of
September 30, 2009.
In
addition, the calculations in the foregoing table do not take into account any
of the following:
|
·
|
1,999,833
shares subject to outstanding options as of September 30, 2009, having a
weighted average exercise price of $3.21, 254,668 of which have been
exercised through the date
hereof;
|
|
·
|
755,961
shares subject to outstanding warrants as of September 30, 2009,
having a weighted average exercise price of $4.08, 522,655 of which have
been exercised through the date
hereof;
|
|
·
|
145,000
shares subject to options granted subsequent to September 30, 2009, having
a weighted average exercise price of
$6.35
|
To the extent that any of our
outstanding options or warrants are exercised, we grant additional options under
our stock option plans or issue additional warrants, or we issue additional
shares of common stock in the future, there may be further dilution to new
investors.
PLAN
OF DISTRIBUTION
Merriman
Curhan Ford & Co., referred to as the placement agent, has entered into a
placement agency agreement, dated as of March 8, 2010, with us in which it has
agreed to act as placement agent in connection with the
offering. Subject to the terms and conditions contained in the
placement agency agreement, the placement agent is using its commercially
reasonable efforts to introduce us to potential investors who will purchase the
securities. The placement agent may engage selected dealers to assist
in the placement of shares and Morgan Keegan & Company, Inc. has agreed to
act as a selected dealer in the offering. The placement agent is not
purchasing or selling any shares offered by this prospectus supplement nor is it
required to arrange the purchase or sale of any specific number of shares, but
has agreed to use its commercially reasonable efforts to arrange for the sale of
all of the shares offered hereby. The placement agent has solicited indications
of interest from investors for the full amount of the offering. We will enter
into subscription agreements directly with investors in connection with this
offering and we may not sell all the shares offered pursuant to this prospectus
supplement.
Any
compensation paid by us to the placement agent in connection with the offering
of the securities offered in this prospectus supplement, and any discounts,
concessions or commissions allowed by the placement agent to participating
dealers, are set forth below. In no event will the total amount of
compensation paid to any member of The Financial Industry Regulatory Authority
upon completion of the offering exceed 8.0% of the maximum gross proceeds of
such offering.
We have agreed to pay the placement
agent a fee equal to 6.0% of the proceeds of this offering, except for shares
sold to certain investors. The following table shows the per share and total
fees we will pay to the placement agent in connection with the sale of the
shares offered pursuant to this prospectus supplement assuming the sale of all
of the shares offered hereby and that the placement agent receives a fee for all
of the shares sold.
Per
Share
|
$0.33
|
Total
|
$736,500
|
Because
there is no minimum offering amount required as a condition to closing in this
offering, the actual total offering commissions, if any, are not presently
determinable and may be substantially less than the maximum amount set forth
above.
We have
also agreed to reimburse the placement agent, on a fully accountable basis, for
all reasonable travel, legal and other out-of-pocket expenses that it incurs in
connection with the offering; provided, however, that individual out-of-pocket
expense items in excess of $2,500 and out-of-pocket expenses (excluding legal
expenses) in excess of $10,000 will require our approval, such approval not to
be unreasonably withheld or delayed. We have agreed to pay the
reasonable fees, disbursements and other charges of counsel to the placement
agent up to an aggregate of $60,000.
Unless
other arrangements are made with a particular investor, all investor funds will
be delivered directly to us. We have not accepted any investor funds prior to
the date of this prospectus supplement.
Our
obligation to issue and sell shares to the investors is subject to the
conditions set forth in the placement agency agreement, which may be waived by
us at our discretion. An investor’s obligation to purchase shares is subject to
the conditions set forth in the subscription agreement as well, which may also
be waived.
We
currently anticipate that the sale of the shares of common stock offered hereby
will be completed on or about March 11, 2010. At the closing, The Depository
Trust Company will credit the shares of common stock to the respective accounts
of the investors.
We have
agreed to indemnify the placement agent and certain other persons against
certain liabilities under the Securities Act.
This is a
brief summary of the material provisions of the placement agency agreement and
does not purport to be a complete statement of its terms and conditions. The
placement agency agreement and the form of subscription agreement will be
exhibits to our Form 8-K to be filed with the SEC on or about March 9, 2010, and
will be incorporated by reference into the registration statement of which this
prospectus supplement forms a part from and after that date. See
“Where You Can Find More Information” on page S-8.
The
placement agent has informed us that it will not engage in over-allotment,
stabilizing transactions or syndicate covering transactions in connection with
this offering.
LEGAL
MATTERS
The
validity of the issuance of securities offered by this prospectus supplement
will be passed upon for us by Eilenberg & Krause LLP, New York, New
York. Lowenstein Sandler, PC, Roseland, New Jersey has represented
the placement agent in connection with the offering.
EXPERTS
The
consolidated financial statements as of December 31, 2008 and 2007, and for each
of the three years in the period ended December 31, 2008, incorporated in this
Prospectus by reference from the Company's Annual Report on Form 10-K, have been
audited by Kesselman & Kesselman, a member of PricewaterhouseCoopers
International Limited, an independent registered public accounting firm, as
stated in their report which is incorporated herein by
reference. Such consolidated financial statements have been so
included in reliance upon the report of such firm given upon their authority as
experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We file
reports, proxy statements and other information with the SEC. Copies
of our reports, proxy statements and other information may be inspected and
copied at the SEC’s Public Reference Room at 100 F. Street, N.E., Washington,
D.C. 20549. Copies of these materials can also be obtained by mail at
prescribed rates from the Public Reference Room of the SEC, 100 F. Street, N.E.,
Washington, D.C. 20549. You may obtain information on the operation
of the Public Reference Room by calling the SEC at
1-800-SEC-0330. The SEC maintains an internet site that contains
reports, proxy and information statements and other information regarding our
company and other issuers that file electronically with the SEC. The
address of the SEC internet site is www.sec.gov.
This information is also available on our website at
www.acornenergy.com. Information contained in our website does not
constitute part of this prospectus supplement or the base
prospectus.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The SEC
allows us to “incorporate by reference” into this prospectus the information we
have filed with the SEC. This means that we can disclose important information
by referring you to those documents. All documents that we subsequently file
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
prior to the termination of this offering, will be deemed to be incorporated by
reference into this prospectus and to be a part hereof from the date of filing
of such documents. Unless expressly incorporated into this prospectus, a Current
Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be
incorporated by reference into this prospectus. Any statement contained in a
document incorporated or deemed to be incorporated by reference in this
prospectus shall be deemed to be modified or superseded for purposes of this
prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus.
We
incorporate by reference the following documents that we have filed with the SEC
and any filings that we will make with the SEC in the future under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act until this offering is
terminated:
|
·
|
Annual
Report on Form 10-K for the fiscal year ended December 31,
2008;
|
|
·
|
Quarterly
Report on Form 10-Q for the fiscal quarter ended March 31,
2009;
|
|
·
|
Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30,
2009;
|
|
·
|
Quarterly
Report on Form 10-Q, and amended on Form 10-Q/A, for the fiscal quarter
ended September 30, 2009;
|
|
·
|
Current
Report on Form 8-K filed February 19,
2009;
|
|
·
|
Current
Report on Form 8-K filed February 25,
2009;
|
|
·
|
Current
Report on Form 8-K filed March 16,
2009;
|
|
·
|
Current
Report on Form 8-K filed April 13, 2009 and amended on Form 8-K/A filed
April 15, 2009;
|
|
·
|
Current
Report on Form 8-K filed August 3,
2009;
|
|
·
|
Current
Report on Form 8-K filed August 18,
2009;
|
|
·
|
Current
Report on Form 8-K filed September 9,
2009;
|
|
·
|
Current
Report on Form 8-K filed October 23,
2009;
|
|
·
|
Current
Report on Form 8-K filed October 27,
2009;
|
|
·
|
Current
Report on Form 8-K filed November 5,
2009;
|
|
·
|
Current
Report on Form 8-K filed December 31,
2009;
|
|
·
|
Current
Report on Form 8-K filed February 24, 2010 (except for the portions
thereof furnished under Item 7.01 and the exhibit referenced
therein);
|
|
·
|
Current
Report on Form 8-K filed March 4, 2010;
and
|
|
·
|
The
description of our Common Stock contained in our Form 8-A filed December
13, 2007.
|
Copies of
these filings are available free of charge by writing to Acorn Energy, Inc., 4
West Rockland Road, Montchanin, Delaware 19710, Attention: Joe B. Cogdell, Jr.,
Secretary, or by telephoning us at (302) 656-1707. We will also provide to each
person, including any beneficial owner, to whom a prospectus is delivered, a
copy of any or all of the information that has been incorporated by reference in
this prospectus supplement but not delivered with this prospectus supplement.
See “Where You Can Find More Information.”
Any
statement made in this prospectus supplement concerning the contents of any
contract, agreement or other document is only a summary of the actual document.
You may obtain a copy of any document summarized in this prospectus at no cost
by writing to or telephoning us at the address and telephone number given above.
Each statement regarding a contract, agreement or other document is qualified in
its entirety by reference to the actual document.
PROSPECTUS
$12,000,000
Common
Stock
Debt
Securities
Warrants
Rights
Units
The
securities covered by this prospectus may be offered and sold by us from time to
time. When we offer securities, we will provide you with a prospectus supplement
describing the specific terms of the specific issue of securities, including the
offering price of the securities. You should carefully read this prospectus and
the prospectus supplement relating to the specific issue of securities, together
with the documents incorporated by reference into this prospectus and any
prospectus supplement, before you decide to purchase any of these
securities.
THIS
PROSPECTUS MAY NOT BE USED TO OFFER OR SELL ANY SECURITIES UNLESS ACCOMPANIED BY
A PROSPECTUS SUPPLEMENT.
We may
offer the securities from time to time in amounts and on terms as we may
determine through public or private transactions or through other means
described in the section entitled “Plan of Distribution” beginning on page 13 of
this prospectus. We may offer and sell these securities to or through one or
more underwriters, dealers and agents, or directly to purchasers, on a
continuous or delayed basis. The applicable prospectus supplement will provide
the specific terms of the plan of distribution for the securities covered by
such prospectus supplement.
Our
common stock is listed on The Nasdaq Global Market under the ticker symbol
“ACFN.” The last reported sale price of our common stock on September 8, 2009
was $4.55 per share. As of September 8, 2009, the aggregate market
value of our outstanding common stock held by non-affiliates was approximately
$47.6 million, based on 11,187,636 shares outstanding, of which approximately
10,466,585 shares were held by non-affiliates. As of the date hereof,
we have not offered any securities pursuant to General Instruction I.B.6 of Form
S-3 during the prior 12 calendar month period that ends on and includes the date
hereof.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning
on page 3 of this prospectus. You should carefully review the risks and
uncertainties described under the heading “Risk Factors” contained in the
applicable prospectus supplement and any related free writing prospectus, and
under similar headings in the other documents that are incorporated by reference
into this prospectus.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date
of this prospectus is September 16, 2009.
You should rely only on the
information contained or incorporated by reference in this prospectus. We have
not authorized anyone to provide you with different or additional information.
We are not making an offer of these securities in any state where the
offer is not permitted. You should not assume that the information provided by this
prospectus is accurate as of any date other than the date on the front of
this prospectus. Our business, financial condition, results of operations and
prospects may have changed since then.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
|
|
1
|
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
|
1
|
ABOUT
ACORN ENERGY
|
|
2
|
RISK
FACTORS
|
|
3
|
USE
OF PROCEEDS
|
|
3
|
SECURITIES
WE MAY OFFER
|
|
3
|
DESCRIPTION
OF CAPITAL STOCK
|
|
4
|
DESCRIPTION
OF DEBT SECURITIES
|
|
5
|
DESCRIPTION
OF WARRANTS
|
|
11
|
DESCRIPTION
OF RIGHTS
|
|
13
|
DESCRIPTION
OF UNITS
|
|
13
|
PLAN
OF DISTRIBUTION
|
|
13
|
LEGAL
MATTERS
|
|
16
|
EXPERTS
|
|
16
|
WHERE
YOU CAN FIND MORE INFORMATION
|
|
16
|
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
|
|
16
|
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-3 that we filed with
the Securities and Exchange Commission, or the SEC, using a “shelf” registration
process. Under this shelf registration process, we may, from time to time, offer
and/or sell the securities referenced herein in one or more offerings up to a
total amount of $12,000,000. This prospectus includes a general description of
the securities we may offer. Each time we offer our securities, we will provide
a prospectus supplement that will contain more specific information about the
offering. The prospectus supplement may also add, update or change information
contained in this prospectus. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information
relating to these offerings. If there is any inconsistency between the
information in this prospectus and a prospectus supplement, you should rely on
the information in that prospectus supplement. In addition, a prospectus
supplement may include a discussion of any risk factors in addition to those
described in this prospectus. You should read both this prospectus and any
accompanying prospectus supplement or free writing prospectus together with the
additional information described under the headings “Where You Can Find More
Information” and “Incorporation of Certain Documents by Reference.”
You
should rely only on the information contained in this prospectus, any applicable
prospectus supplement and those documents incorporated by reference herein. We
have not authorized anyone to provide you with different information. This
prospectus may only be used where it is legal to sell these securities. This
prospectus is not an offer to sell, or a solicitation of an offer to buy, in any
state where the offer or sale is prohibited. The information in this prospectus,
any prospectus supplement or any document incorporated herein or therein by
reference is accurate as of the date contained on the cover of such documents.
Neither the delivery of this prospectus or any prospectus supplement, nor any
sale made under this prospectus or any prospectus supplement will, under any
circumstances, imply that the information in this prospectus or any prospectus
supplement is correct as of any date after the date of this prospectus or any
such prospectus supplement.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the registration statement of which it forms a part, any
prospectus supplement and the documents incorporated by reference into these
documents contain forward-looking statements within the meaning of Section 27A
of the Securities Act, and Section 21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. We use words such as “anticipates,” “believes,”
“plans,” “expects,” “future,” “intends,” “will,” “foresee” and similar
expressions to identify these forward-looking statements. These forward-looking
statements are subject to certain known and unknown risks and uncertainties, as
well as assumptions that could cause actual results to differ materially from
those reflected in these forward-looking statements. Factors that might cause
actual results to differ include, but are not limited to, those referenced in
the section entitled “Risk Factors” beginning on page 3 of this prospectus.
Readers are cautioned not to place undue reliance on any forward-looking
statements contained herein, which reflect management’s opinions only as of the
date hereof. Except as required by law, we undertake no obligation to revise or
publicly release the results of any revision to any forward-looking statements.
You are advised, however, to consult any additional disclosures we have made or
will make in our reports to the SEC on Forms 10-K, 10-Q and 8-K. All subsequent
written and oral forward-looking statements attributable to us or persons acting
on our behalf are expressly qualified in their entirety by the cautionary
statements contained in this prospectus.
ABOUT
ACORN ENERGY
This summary description of us and
our business highlights selected information contained elsewhere in
this prospectus or incorporated herein by reference. This summary may not
contain all of the information that you should consider before buying securities in
this offering. You should carefully read this entire prospectus and any
applicable prospectus supplement or free writing prospectus, including each of the
documents incorporated herein or therein by reference, before making an
investment decision. As used herein, “we,” “us,” and “our” refer to Acorn Energy and
its subsidiaries.
Our
Company
Acorn
Energy is a holding company focused on improving the efficiency and
environmental impact of the energy infrastructure, fossil fuel and nuclear
industries. Our operating companies leverage advanced technologies to transform
the existing energy infrastructure. We aim to acquire primarily controlling
positions in companies led by promising entrepreneurs and we add value by
supporting those companies with financing, branding, positioning, and strategy
and business development.
Through
our majority-owned operating subsidiaries and a company in which we own a
significant equity interest we provide the following services:
· SCR Catalyst and Management Services.
We provide selective catalytic reduction (“SCR”) management and catalyst
regeneration services for coal-fired power plants. These services
include SCR catalyst management, cleaning and regeneration as well as consulting
services to help power plant operators to optimize efficiency and reduce overall
nitrogen oxide compliance costs through CoaLogix’s SCR-Tech LLC
subsidiary.
· Naval and RT
Solutions. We provide sonar and acoustic related solutions for
energy, defense and commercial markets with a focus on underwater site security
for strategic energy installations and other real-time and embedded hardware and
software development and production through our DSIT subsidiary.
· Energy Infrastructure Software (EIS)
Services. We provide energy infrastructure software services through our
Coreworx Inc. subsidiary. Coreworx is a leading provider of integrated project
collaboration and advanced document management solutions for the architecture,
engineering and construction markets, particularly for large capital projects in
the energy industry.
· GridSense Systems Inc., in
which we own a significant equity interest, provides remote monitoring and
control systems to electric utilities and industrial facilities
worldwide.
Our
Corporate Information
Our
executive offices are located at 4 West Rockland Road, Montchanin, Delaware
19710, our telephone number at that location is (302) 656-1707, and our website
can be accessed at www.acornenergy.com. Information contained in our
website does not constitute part of this prospectus.
RISK
FACTORS
An investment in our securities
involves a high degree of risk. You should carefully consider the specific
risks described under the heading “Risk Factors” in the applicable
prospectus supplement, and under the caption “Risk Factors” in any of our filings with
the SEC pursuant to Sections 13(a), 14 or 15(d) of the Exchange Act, which are
incorporated herein by reference, before making an investment decision. Each
of the risks described could adversely and materially affect our business,
financial conditions and operating results. As a result, the
trading price of our common stock could decline and you may lose all or a
part of your investment in our common stock. For more information see “Where You
Can Find More Information” and “Incorporation of Certain Documents
By Reference,” on page 16 of this prospectus.
USE
OF PROCEEDS
Unless we
state otherwise in the applicable prospectus supplement accompanying this
prospectus, we expect to add substantially all of the net proceeds of the sale
of securities by us to our general funds for general corporate purposes,
including working capital, the repayment or reduction of long-term and
short-term debt and possible acquisitions. We may invest funds that
we do not immediately require in short-term marketable securities.
From time
to time, we may engage in additional public or private financings of a character
and amount which we may deem appropriate.
SECURITIES
WE MAY OFFER
We may,
from time to time offer under this prospectus, separately or
together:
• common
stock;
• debt
securities;
• warrants
to purchase securities;
• rights
to purchase common stock; and
• units.
The
aggregate initial offering price of the offered securities will not exceed
$12,000,000.
DESCRIPTION
OF CAPITAL STOCK
General
Our
Certificate of Incorporation, as amended, (the “Certificate of Incorporation”)
authorizes 20,000,000 shares of capital stock, all of which has been designated
as common stock, $.01 par value per share. We do not have any authorized
preferred stock. The foregoing and the following description of capital stock
give effect to the Certificate of Incorporation and the provisions of the
applicable Delaware law.
Common
Stock
The
holders of common stock are entitled to one vote per share on all matters to be
voted upon by the stockholders. The holders of common stock are entitled to
receive ratably any dividends that may be declared from time to time by the
board of directors out of funds legally available for that purpose. In the event
of our liquidation, dissolution or winding up, the holders of our common stock
are entitled to share ratably in all assets remaining after payment of
liabilities. The common stock has no preemptive or conversion rights or other
subscription rights.
Warrants
and Options
As of
August 31, 2009, warrants to purchase 778,334 shares of our common stock at a
weighted average exercise price of $4.07 per share, and options to
purchase 1,999,833 shares of our common stock at a weighted average exercise
price of $3.21 per share, were outstanding.
Anti-Takeover
Provisions
Our
By-Laws establish an advance notice procedure for stockholder proposals to be
brought before an annual meeting of our stockholders, including proposed
nominations of persons for election to the board of directors. At an
annual meeting, stockholders may consider a proposal or nomination by a person
who was a stockholder of record on the record date for the meeting, who is
entitled to vote at the meeting and who has given to the Secretary timely
written notice, in proper form, of his or her intention to bring that business
before the meeting. Our By-laws do not give the board of directors
the power to approve or disapprove stockholder nominations of candidates or
proposals regarding other business to be conducted at a special or annual
meeting of the stockholders. However, our By-laws may have the effect
of precluding the conduct of certain business at a meeting if the proper
procedures are not followed. These provisions may also discourage or
deter a potential acquirer from conducting a solicitation of proxies to elect
the acquirer’s own slate of directors or otherwise attempting to obtain control
of us.
Under
Delaware law, a special meeting of stockholders may be called by the board of
directors or by any other person authorized to do so in our Certificate of
Incorporation or our By-Laws. Our By-Laws authorize only our board of
directors or our President to call a special meeting of
stockholders. Because our stockholders do not have the right to call
a special meeting, a stockholder could not force stockholder consideration of a
proposal over the opposition of the board of directors by calling a special
meeting of stockholders prior to such time as a majority of the board of
directors believed or the President believed the matter should be considered or
until the next annual meeting provided that the requestor met the notice
requirements. The restriction on the ability of stockholders to call
a special meeting means that a proposal to replace the board also could be
delayed until the next annual meeting.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is American Stock Transfer and
Trust Company LLC, 59 Maiden Lane, Plaza Level, New York, NY 10038.
DESCRIPTION
OF DEBT SECURITIES
This
prospectus describes the general terms and provisions of the debt securities we
may offer and sell by this prospectus. When we offer to sell a particular series
of debt securities, we will describe the specific terms of the series in a
prospectus supplement. We will also indicate in the prospectus supplement
whether the general terms and provisions described in this prospectus apply to a
particular series of debt securities.
We may
offer under this prospectus up to $12,000,000 in aggregate principal amount of
debt securities, or if debt securities are issued at a discount, or in a foreign
currency or composite currency, such principal amount as may be sold for an
initial offering price of up to $12,000,000. We may offer debt securities in the
form of either senior debt securities or subordinated debt securities. The
senior debt securities and the subordinated debt securities are together
referred to in this prospectus as the “debt securities.” Unless otherwise
specified in a prospectus supplement, the senior debt securities will be our
direct, unsecured obligations and will rank equally with all of our other
unsecured and unsubordinated indebtedness. The subordinated debt securities
generally will be entitled to payment only after payment of our senior
debt.
The debt
securities will be issued under an indenture between us and a trustee, the form
of which is filed as an exhibit to the registration statement of which this
prospectus forms a part. We have summarized the general features of the debt
securities to be governed by the indenture. The summary is not complete. The
executed indenture will be incorporated by reference from a report on Form 8-K.
We encourage you to read the indenture, because the indenture, and not this
summary, will govern your rights as a holder of debt securities. Capitalized
terms used in this summary will have the meanings specified in the indenture.
References to “we,” “us” and “our” in this section, unless the context otherwise
requires or as otherwise expressly stated, refer to Acorn Energy, Inc.,
excluding its subsidiaries.
Additional
Information
The
terms of each series of debt securities will be established by or pursuant to a
resolution of our board of directors, or a committee thereof, and set forth or
determined in the manner provided in an officers’ certificate or by a
supplemental indenture. The particular terms of each series of debt securities
will be described in a prospectus supplement relating to such series, including
any pricing supplement.
We may
issue an unlimited amount of debt securities under the indenture, and the debt
securities may be in one or more series with the same or various maturities, at
par, at a premium or at a discount. Except as set forth in any prospectus
supplement, we will also have the right to “reopen” a previous series of debt
securities by issuing additional debt securities of such series without the
consent of the holders of debt securities of the series being reopened or any
other series. Any additional debt securities of the series being reopened will
have the same ranking, interest rate, maturity and other terms as the previously
issued debt securities of that series. These additional debt securities,
together with the previously issued debt securities of that series, will
constitute a single series of debt securities under the terms of the applicable
indenture.
We will
set forth in a prospectus supplement, including any pricing supplement, relating
to any series of debt securities being offered, the aggregate principal amount
and other terms of the debt securities, which will include some or all of the
following:
|
·
|
any
limit on the amount that may be
issued;
|
|
·
|
whether
or not we will issue the series of debt securities in global form, and, if
so, the terms and the name of the
depository;
|
|
·
|
the
interest rate, which may be fixed or variable, or the method for
determining the rate and the date interest will begin to accrue, the dates
interest will be payable and the regular record dates for interest payment
dates or the method for determining such
dates;
|
|
·
|
whether
or not the debt securities will be secured or unsecured, and the terms of
any securities;
|
|
·
|
classification
as senior or subordinated debt
securities;
|
|
·
|
in
the case of subordinated debt securities, the degree, if any, to which the
subordinated debt securities of the series will be senior to or be
subordinated to other indebtedness of our in right of payment, whether the
other indebtedness is outstanding or
not;
|
|
·
|
the
terms on which any series of debt securities may be convertible into or
exchangeable for our common stock or other of our securities, including
(a) provisions as to whether conversion or exchange is mandatory, at the
option of the holder or at our option and (b) provisions pursuant to which
the number of shares of common stock or other securities of ours that the
holders of the series of debt securities receive would be subject to
adjustment;
|
|
·
|
the
place where payments will be
payable;
|
|
·
|
our
right, if any, to defer payment of interest and the maximum length of any
such deferral period;
|
|
·
|
the
date, if any, after which, and the price at which, we may, at our option,
redeem the series of debt securities pursuant to any optional redemption
provisions;
|
|
·
|
the
date, if any, on which, and the price at which we are obligated, pursuant
to any mandatory sinking fund provisions or otherwise, to redeem, or at
the holder’s option to purchase, the series of debt
securities;
|
|
·
|
whether
the indenture will restrict our ability to pay dividends, or will require
us to maintain any asset ratios or
reserves;
|
|
·
|
whether
we will be restricted from incurring any additional
indebtedness;
|
|
·
|
any
listing of a series of debt securities on a securities exchange or
market;
|
|
·
|
the
denominations in which we will issue the series of debt securities, if
other than denominations of $1,000 and any integral multiple thereof;
and
|
|
·
|
any
other specific terms, preferences, rights or limitations of, or
restrictions on, the debt
securities.
|
We will
provide information on the applicable United States income tax considerations
and other special considerations applicable to any of these debt securities in
the applicable prospectus supplement.
If we
denominate the purchase price of any of the debt securities in a foreign
currency or currencies or a foreign currency unit or units, or if the principal
of, and premium and interest on, any series of debt securities is payable in a
foreign currency or currencies or a foreign currency unit or units, we will
provide you with information on the restrictions, elections, general tax
considerations, specific terms and other information with respect to that issue
of debt securities and such foreign currency or currencies or foreign currency
unit or units in the applicable prospectus supplement.
Transfer
And Exchange
Each debt
security will be represented by either one or more global securities registered
in the name of The Depositary Trust Company, as Depositary, or a nominee (we
will refer to any debt security represented by a global debt security as a
“book-entry debt security”), or a certificate issued in definitive registered
form (we will refer to any debt security represented by a certificated security
as a “certificated debt security”) as set forth in the applicable prospectus
supplement.
You may
transfer or exchange certificated debt securities at any office we maintain for
this purpose in accordance with the terms of the indenture. No service charge
will be made for any transfer or exchange of certificated debt securities, but
we may require payment of a sum sufficient to cover any tax or other
governmental charge payable in connection with a transfer or
exchange.
You may
effect the transfer of certificated debt securities and the right to receive the
principal of, and any premium and interest on, certificated debt securities only
by surrendering the certificate representing those certificated debt securities
and either reissuance by us or the trustee of the certificate to the new holder
or the issuance by us or the trustee of a new certificate to the new
holder.
No Protection in the Event of a
Change of Control
Unless
we state otherwise in the applicable prospectus supplement, the debt securities
will not contain any provisions which may afford holders of the debt securities
protection in the event we undergo a change in control or in the event of a
highly leveraged transaction (whether or not such transaction results in a
change in control) which could adversely affect holders of debt
securities.
Covenants
We
will set forth in the applicable prospectus supplement any restrictive covenants
applicable to any issue of debt securities.
Consolidation,
Merger and Sale of Assets
We
may not consolidate with or merge with or into, or convey, transfer or lease all
or substantially all of our properties and assets to, any person, which we refer
to as a successor person, unless:
|
·
|
we
are the surviving corporation or the successor person (if other than us)
expressly assumes our obligations on the debt securities and under the
indenture;
|
|
·
|
immediately
after giving effect to the transaction, no event of default, and no event
which, after notice or lapse of time, or both, would become an event of
default, shall have occurred and be continuing under the indenture;
and
|
|
·
|
certain
other conditions are met, including any additional conditions described in
the applicable prospectus
supplement.
|
Events of Default
Event of
default means, with respect to any series of debt securities, any of the
following:
|
·
|
default
in the payment of any interest upon any debt security of that series when
it becomes due and payable, and continuance of that default for a period
of 30 days (unless the entire amount of the payment is deposited by us
with the trustee or with a paying agent prior to the expiration of the
30-day period);
|
|
·
|
default
in the payment of principal of or premium on any debt security of that
series when due and payable;
|
|
·
|
default
in the performance or breach of any other covenant or warranty by us in
the indenture (other than a covenant or warranty that has been included in
the indenture solely for the benefit of a series of debt securities other
than that series), which default continues uncured for a period of 90 days
after we receive written notice from the trustee or we and the trustee
receive written notice from the holders of not less than a majority in
principal amount of the outstanding debt securities of that series as
provided in the indenture;
|
|
·
|
certain
events of bankruptcy, insolvency or reorganization of our company;
and
|
|
·
|
any
other event of default provided with respect to debt securities of that
series that is described in the applicable prospectus
supplement.
|
No
event of default with respect to a particular series of debt securities (except
as to certain events of bankruptcy, insolvency or reorganization) necessarily
constitutes an event of default with respect to any other series of debt
securities. The occurrence of an event of default may constitute an event of
default under our bank credit agreements in existence from time to time. In
addition, the occurrence of certain events of default or an acceleration under
the indenture may constitute an event of default under certain of our other
indebtedness outstanding from time to time.
If an
event of default with respect to debt securities of any series at the time
outstanding occurs and is continuing, then the trustee or the holders of not
less than a majority in principal amount of the outstanding debt securities of
that series may, by a notice in writing to us (and to the trustee if given by
the holders), declare to be due and payable immediately the principal (or, if
the debt securities of that series are discount securities, that portion of the
principal amount as may be specified in the terms of that series) of, and
accrued and unpaid interest, if any, on all debt securities of that series. In
the case of an event of default resulting from certain events of bankruptcy,
insolvency or reorganization, the principal (or such specified amount) of and
accrued and unpaid interest, if any, on all outstanding debt securities will
become and be immediately due and payable without any declaration or other act
on the part of the trustee or any holder of outstanding debt securities. At any
time after a declaration of acceleration with respect to debt securities of any
series has been made, but before a judgment or decree for payment of the money
due has been obtained by the trustee, the holders of a majority in principal
amount of the outstanding debt securities of that series may rescind and annul
the acceleration if all events of default, other than the non-payment of
accelerated principal and interest, if any, with respect to debt securities of
that series, have been cured or waived as provided in the indenture. We refer
you to the prospectus supplement relating to any series of debt securities that
are discount securities for the particular provisions relating to acceleration
of a portion of the principal amount of such discount securities upon the
occurrence of an event of default.
The
indenture provides that the trustee will be under no obligation to exercise any
of its rights or powers under the indenture at the request of any holder of
outstanding debt securities, unless the trustee receives indemnity satisfactory
to it against any loss, liability or expense. Subject to certain rights of the
trustee, the holders of a majority in principal amount of the outstanding debt
securities of any series will have the right to direct the time, method and
place of conducting any proceeding for any remedy available to the trustee or
exercising any trust or power conferred on the trustee with respect to the debt
securities of that series.
No holder
of any debt security of any series will have any right to institute any
proceeding, judicial or otherwise, with respect to the indenture or for the
appointment of a receiver or trustee, or for any remedy under the indenture,
unless:
|
·
|
that
holder has previously given to the trustee written notice of a continuing
event of default with respect to debt securities of that series;
and
|
|
·
|
the
holders of at least a majority in principal amount of the outstanding debt
securities of that series have made written request, and offered
reasonable indemnity, to the trustee to institute the proceeding as
trustee, and the trustee has not received from the holders of a majority
in principal amount of the outstanding debt securities of that series a
direction inconsistent with that request and has failed to institute the
proceeding within 60 days.
|
Notwithstanding
the foregoing, the holder of any debt security will have an absolute and
unconditional right to receive payment of the principal of, and any premium and
interest on, that debt security on or after the due dates expressed in that debt
security and to institute suit for the enforcement of payment.
If any
securities are outstanding under the indenture, the indenture requires us,
within 120 days after the end of our fiscal year, to furnish to the trustee
a statement as to compliance with the indenture. The indenture provides that the
trustee may withhold notice to the holders of debt securities of any series of
any default or event of default (except in payment on any debt securities of
that series) with respect to debt securities of that series if it in good faith
determines that withholding notice is in the interest of the holders of those
debt securities.
Modification
And Waiver
We
may modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series
affected by the modifications or amendments. We may not make any modification or
amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will:
|
·
|
reduce
the amount of debt securities whose holders must consent to an amendment
or waiver;
|
|
·
|
reduce
the rate of or extend the time for payment of interest (including default
interest) on any debt security;
|
|
·
|
reduce
the principal of, or premium on, or change the fixed maturity of, any debt
security or reduce the amount of, or postpone the date fixed for, the
payment of any sinking fund or analogous obligation with respect to any
series of debt securities;
|
|
·
|
reduce
the principal amount of discount securities payable upon acceleration of
maturity;
|
|
·
|
waive
a default in the payment of the principal of, or premium or interest on,
any debt security (except a rescission of acceleration of the debt
securities of any series by the holders of at least a majority in
aggregate principal amount of the then outstanding debt securities of that
series and a waiver of the payment default that resulted from such
acceleration);
|
|
·
|
make
the principal of, or premium or interest on, any debt security payable in
currency other than that stated in the debt
security;
|
|
·
|
make
any change to certain provisions of the indenture relating to, among other
things, the right of holders of debt securities to receive payment of the
principal of, and premium and interest on, those debt securities and to
institute suit for the enforcement of any such payment and to waivers or
amendments; or
|
|
·
|
waive
a redemption payment with respect to any debt
security.
|
Except
for certain specified provisions, the holders of at least a majority in
principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with
provisions of the indenture. The holders of a majority in principal amount of
the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the
indenture with respect to that series and its consequences, except a default in
the payment of the principal of, or any premium or interest on, any debt
security of that series or in respect of a covenant or provision, which cannot
be modified or amended without the consent of the holder of each outstanding
debt security of the series affected; provided, however, that the
holders of a majority in principal amount of the outstanding debt securities of
any series may rescind an acceleration of the debt securities of such series and
its consequences, including any related payment default that resulted from the
acceleration.
Discharging
Our Obligations
We may
choose to either discharge our obligations on the debt securities of any series
in a legal defeasance, or to release ourselves from our covenant restrictions on
the debt securities of any series in a covenant defeasance. We may do so at any
time after we deposit with the trustee sufficient cash or government securities
to pay the principal, interest, any premium and any other sums due to the stated
maturity date or a redemption date of the debt securities of the series. If we
choose the legal defeasance option, the holders of the debt securities of the
series will not be entitled to the benefits of the indenture except for
registration of transfer and exchange of debt securities, replacement of lost,
stolen, destroyed or mutilated debt securities, conversion or exchange of debt
securities, sinking fund payments and receipt of principal and interest on the
original stated due dates or specified redemption dates.
We may
discharge our obligations under the indenture or release ourselves from covenant
restrictions only if, in addition to making the deposit with the trustee, we
meet some specific requirements. Among other things:
|
·
|
we
must deliver an opinion of our legal counsel that the discharge will not
result in holders having to recognize taxable income or loss or subject
them to different tax treatment. In the case of legal defeasance, this
opinion must be based on either an IRS letter ruling or change in federal
tax law;
|
|
·
|
we
may not have a default on the debt securities discharged on the date of
deposit;
|
|
·
|
the
discharge may not violate any of our agreements;
and
|
|
·
|
the
discharge may not result in our becoming an investment company in
violation of the Investment Company Act of
1940.
|
Governing
Law
The indenture and the debt securities
will be governed by, and construed in accordance with, the internal laws of the
State of New York, without regard to conflict of law principles that would
result in the application of any law other than the laws of the State of New
York.
DESCRIPTION
OF WARRANTS
We may
issue, either separately or together with other securities, warrants for the
purchase of any securities, including any combination of common stock or debt
securities that we may sell under this prospectus. Warrants may be issued
separately or together with other securities.
The
warrants will be issued under warrant agreements to be entered into between us
and the warrantholder as set forth in the applicable prospectus supplement
relating to any or all warrants with respect to which this prospectus is being
delivered. Copies of the form of agreement for each warrant, which we refer to
collectively as “warrant agreements,” including the forms of certificates
representing the warrants, which we refer to collectively as “warrant
certificates,” and reflecting the provisions to be included in such agreements
that will be entered into with respect to a particular offering of each type of
warrant, will be filed with the SEC and incorporated by reference as exhibits to
the registration statement of which this prospectus is a part or as an exhibit
to a Current Report on Form 8-K.
The
following description sets forth certain general terms and provisions of the
warrants to which any prospectus supplement may relate. The particular terms of
the warrants to which any prospectus supplement may relate and the extent, if
any, to which the general provisions may apply to the warrants so offered will
be described in the applicable prospectus supplement. To the extent that any
particular terms of the warrants, warrant agreements or warrant certificates
described in a prospectus supplement differ from any of the terms described in
this section, then the terms described in this section will be deemed to have
been superseded by that prospectus supplement. We encourage you to read the
applicable warrant agreement and certificate for additional information before
you purchase any of our warrants.
General
The
prospectus supplement will describe the terms of the warrants with respect to
which this prospectus is being delivered, as well as the related warrant
agreement and warrant certificates, including the following, where
applicable:
|
•
|
the
principal amount of, or the number of, securities, as the case may be,
purchasable upon exercise of each warrant and the initial price at which
the principal amount or number of securities, as the case may be, may be
purchased upon such exercise;
|
|
•
|
the
designation and terms of the securities, if other than common stock,
purchasable upon exercise of the warrants and of any securities, if other
than common stock, with which the warrants are
issued;
|
|
•
|
the
procedures and conditions relating to the exercise of the
warrants;
|
|
•
|
the
date, if any, on and after which the warrants, and any securities with
which the warrants are issued, will be separately
transferable;
|
|
•
|
the
offering price, if any, of the
warrants;
|
|
•
|
the
date on which the right to exercise the warrants will commence and the
date on which that right will
expire;
|
|
•
|
if
applicable, a discussion of the material United States federal income tax
considerations applicable to the exercise of the
warrants;
|
|
•
|
whether
the warrants represented by the warrant certificates will be issued in
registered or bearer form and, if registered, where they may be
transferred and registered;
|
|
•
|
call
provisions, if any, of the
warrants;
|
|
•
|
antidilution
provisions, if any, of the warrants;
and
|
|
•
|
any
other material terms of the
warrants.
|
The
description of warrants in the prospectus supplement will not necessarily be
complete and will be qualified in its entirety by reference to the warrant
agreement and warrant certificate relating to the warrants being
offered.
Exercise
of Warrants
Each
warrant will entitle the holder to purchase for cash that principal amount of,
or number of, securities, as the case may be, at the exercise price set forth
in, or to be determined as set forth in, the applicable prospectus supplement
relating to the warrants. If mentioned in the relevant prospectus supplement,
securities may be surrendered as all or part of the exercise of the warrants.
Unless otherwise specified in the applicable prospectus supplement, warrants may
be exercised as indicated in the applicable prospectus supplement at any time up
to the close of business, New York City time, on the expiration date set forth
in the applicable prospectus supplement. After the close of business, New York
City time, on the expiration date, unexercised warrants will become void. Upon
receipt of payment and the warrant certificate properly completed and duly
executed, we will, as soon as practicable, issue the securities purchasable upon
exercise of the warrant. If less than all of the warrants represented by the
warrant certificate are exercised, a new warrant certificate will be issued for
the remaining amount of warrants.
No
Rights of Security Holder Prior to Exercise
Before
the exercise of their warrants, holders of warrants will not have any of the
rights of holders of the securities purchasable upon the exercise of the
warrants, and will not be entitled to, among other things, vote or receive
dividend payments or similar distributions on the securities purchasable upon
exercise.
Exchange
of Warrant Certificates
Warrant
certificates may be exchangeable for new warrant certificates of different
denominations as indicated in the applicable prospectus
supplement.
DESCRIPTION
OF RIGHTS
We may
issue rights to our stockholders for the purchase of shares of our common
stock. Each series of rights will be issued under a separate rights
agreement to be entered into between our company and a bank or trust company, as
rights agent, all as set forth in the prospectus supplement relating to the
particular issue of rights. The rights agent will act solely as an
agent of our company in connection with the certificates relating to the rights
of such series and will not assume any obligation or relationship of agency or
trust for or with any holders of rights certificates or beneficial owners of
rights. The rights agreement and the form of rights certificate
relating to each series of rights will be filed with the SEC and incorporated by
reference as an exhibit to the registration statement of which this prospectus
is a part or as an exhibit to a Current Report on Form 8-K. We
encourage you to read the applicable rights agreement and form of rights
certificate before you purchase any of our rights.
DESCRIPTION
OF UNITS
We may
issue units to purchase one or more of the securities referenced
herein. The terms of such units will be set forth in a prospectus
supplement. The form of units and the applicable unit agreement will
be filed with the SEC and incorporated by reference as exhibits to the
registration statement of which this prospectus is a part or as an exhibit to a
Current Report on Form 8-K. We encourage you to read the applicable
unit agreement and form of unit before you purchase any of our
units.
PLAN
OF DISTRIBUTION
We may
sell the offered securities (1) through underwriters or dealers; (2) directly to
purchasers, including our affiliates and shareholders, or in a rights offering;
(3) through agents; or (4) through a combination of any of these methods. The
prospectus supplement will include the following information:
|
·
|
the
terms of the offering;
|
|
·
|
the
names of any underwriters, dealers or
agents;
|
|
·
|
the
name or names of any managing underwriter or
underwriters;
|
|
·
|
the
purchase price of the securities;
|
|
·
|
the
net proceeds from the sale of the
securities;
|
|
·
|
any
over-allotment options under which underwriters may purchase additional
securities from us;
|
|
·
|
any
delayed delivery arrangements;
|
|
·
|
any
underwriting discounts or commissions or agency fees and other items
constituting underwriters' or agent's
compensation;
|
|
·
|
any
discounts, commissions, or concessions allowed or reallowed or
paid to dealers;
|
|
·
|
any
commissions paid to agents; and
|
|
·
|
any
securities exchanges or markets on which the securities may be
listed.
|
Any
initial public offering price and any discounts or concessions allowed or
reallowed or paid to dealers may be changed from time to time.
Underwriters
may offer and sell the offered securities from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. The obligations of
the underwriters to purchase the securities will be subject to the conditions
set forth in the applicable underwriting agreement. If underwriters are used in
the sale of any securities, the securities will be acquired by the underwriters
for their own account and may be resold from time to time in one or more
transactions described above. The securities may be either offered to the public
through underwriting syndicates represented by managing underwriters, or
directly by underwriters. Unless we inform you otherwise in the prospectus
supplement or free-writing prospectus, the underwriters’ obligations to purchase
the securities will be subject to certain conditions precedent and the
underwriters will be obligated to purchase all of the securities if they
purchase any of the securities. We may use underwriters with whom we have a
material relationship. We will describe in the prospectus supplement or free
writing prospectus, naming the underwriter, the nature of any such
relationship.
We may
sell the securities directly or through agents from time to time. The prospectus
supplement or free writing prospectus will name any agent involved in the offer
or sale of the securities and any commissions we pay to them. Unless we inform
you otherwise in the prospectus supplement or free-writing prospectus, any agent
will be acting on a best efforts basis for the period of its
appointment.
We may
sell the securities directly to institutional investors or others who may be
deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. We will describe the terms of any such sales in
the prospectus supplement or free-writing prospectus.
We may
also make direct sales through subscription rights distributed to our existing
stockholders on a pro rata basis that may or may not be transferable. In any
distribution of subscription rights to our stockholders, if all of the
underlying securities are not subscribed for, we may then sell the unsubscribed
securities directly to third parties or we may engage the services of one or
more underwriters, dealers or agents, including standby underwriters, to sell
the unsubscribed securities to third parties.
Offered
securities also may be offered and sold, if so indicated in the applicable
prospectus supplement or free-writing prospectus, in connection with a
remarketing upon their purchase, in accordance with a redemption or repayment
pursuant to their terms, or otherwise, by one or more remarketing firms, acting
as principals for their own accounts or as agents for us. Any remarketing firm
will be identified and the terms of its agreements, if any, with us and its
compensation will be described in the applicable prospectus supplement.
Remarketing firms may be deemed to be underwriters, as that term is defined in
the Securities Act, in connection with the securities remarketed.
We may
engage in at-the-market offerings of our common stock. An at-the-market offering
is an offering of our common stock at other than a fixed price or through a
market maker.
We may
authorize underwriters, dealers or agents to solicit offers by certain
purchasers to purchase the securities from us at the public offering price set
forth in the prospectus supplement or free writing prospectus pursuant to
delayed delivery contracts providing for payment and delivery on a specified
date in the future. The contracts will be subject only to those conditions set
forth in the prospectus supplement or free writing prospectus, and the
prospectus supplement or free writing prospectus will set forth any commissions
we pay for solicitation of these contracts.
Agents
and underwriters may be entitled to indemnification by us against certain civil
liabilities, including liabilities under the Securities Act, or to contribution
with respect to payments which the agents or underwriters may be required to
make in respect thereof. Agents and underwriters may be customers of, engage in
transactions with, or perform services for us in the ordinary course of
business.
All
securities we offer, other than common stock, will be new issues of securities
with no established trading market. Any underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market
making at any time without notice. We cannot guarantee the liquidity of the
trading markets for any securities.
Any
underwriter may engage in overallotment, stabilizing transactions, short
covering transactions and penalty bids in accordance with Regulation M
under the Exchange Act. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to
purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the
securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession
from a dealer when the securities originally sold by the dealer are purchased in
a covering transaction to cover short positions. Those activities may cause the
price of the securities to be higher than it would otherwise be. If commenced,
the underwriters may discontinue any of the activities at any time.
Any
underwriters who are qualified market makers on the Nasdaq Global Market may
engage in passive market making transactions in our common stock, warrants, debt
securities, rights or units, as applicable, on the Nasdaq Global Market in
accordance with Rule 103 of Regulation M, during the business day
prior to the pricing of the offering, before the commencement of offers or sales
of the securities. Passive market makers must comply with applicable volume and
price limitations and must be identified as passive market makers. In general, a
passive market maker must display its bid at a price not in excess of the
highest independent bid for such security; if all independent bids are lowered
below the passive market maker’s bid, however, the passive market maker’s bid
must then be lowered when certain purchase limits are exceeded.
Broker-dealers
engaged by us may arrange for other brokers-dealers to participate in sales.
Broker-dealers may receive commissions or discounts from us (or, if any
broker-dealer acts as agent for the purchaser of shares, from the purchaser) in
amounts to be negotiated, but, except as set forth in a supplement to this
Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with NASD Rule 2440; and in the case of a
principal transaction a markup or markdown in compliance with NASD
IM-2440.
In
connection with the sale of the common stock or interests therein, we may enter
into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of
hedging the positions they assume. We may also sell shares of the common stock
short and deliver these securities to close out their short positions, or loan
or pledge the common stock to broker-dealers that in turn may sell these
securities. We may also enter into option or other transactions with
broker-dealers or other financial institutions or the creation of one or more
derivative securities which require the delivery to such broker-dealer or other
financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such
transaction).
We and
any broker-dealers or agents that are involved in selling the securities may be
deemed to be “underwriters” within the meaning of the Securities Act in
connection with such sales. In such event, any commissions received by such
broker-dealers or agents and any profit on the resale of the securities
purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. In no event shall any broker-dealer receive fees,
commissions and markups which, in the aggregate, would exceed eight percent
(8%).
LEGAL
MATTERS
The
validity of the issuance of securities offered by this prospectus will be passed
upon for us by Eilenberg & Krause LLP, New York, New York.
EXPERTS
The
consolidated financial statements as of December 31, 2008 and 2007, and for each
of the three years in the period ended December 31, 2008, incorporated in this
Prospectus by reference from the Company's Annual Report on Form 10-K, have been
audited by Kesselman & Kesselman, a member of PricewaterhouseCoopers
International Limited, an independent registered public accounting firm, as
stated in their report which is incorporated herein by
reference. Such consolidated financial statements have been so
included in reliance upon the report of such firm given upon their authority as
experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We file
reports, proxy statements and other information with the SEC. Copies
of our reports, proxy statements and other information may be inspected and
copied at the SEC’s Public Reference Room at 100 F. Street, N.E., Washington,
D.C. 20549. Copies of these materials can also be obtained by mail at
prescribed rates from the Public Reference Room of the SEC, 100 F. Street, N.E.,
Washington, D.C. 20549. You may obtain information on the operation
of the Public Reference Room by calling the SEC at
1-800-SEC-0330. The SEC maintains an internet site that contains
reports, proxy and information statements and other information regarding our
company and other issuers that file electronically with the SEC. The
address of the SEC internet site is www.sec.gov. This
information is also available on our website at
www.acornenergy.com. Information contained in our website does not
constitute part of this prospectus.
We have
filed a registration statement on Form S-3 under the Securities Act with the SEC
with respect to the securities to be sold hereunder. This prospectus
has been filed as part of that registration statement. This
prospectus does not contain all of the information set forth in the registration
statement because certain parts of the registration statement are omitted in
accordance with the rules and regulations of the SEC. We will provide
a copy of any and all of the information that is incorporated by reference in
this prospectus, without charge, upon written or oral request. If you
would like to obtain this information from us, please direct your request,
either in writing or by telephone, to Investor Relations, Acorn Energy, Inc., 4
West Rockland Road, Montchanin, DE 19710, Attention: Joe B. Cogdell,
Jr., Secretary, (302) 656-1707.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The SEC
allows us to “incorporate by reference” into this prospectus the information we
have filed with the SEC. This means that we can disclose important information
by referring you to those documents. All documents that we subsequently file
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
prior to the termination of this offering, will be deemed to be incorporated by
reference into this prospectus and to be a part hereof from the date of filing
of such documents. Unless expressly incorporated into this prospectus, a Current
Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be
incorporated by reference into this prospectus. Any statement contained in a
document incorporated or deemed to be incorporated by reference in this
prospectus shall be deemed to be modified or superseded for purposes of this
prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus.
We
incorporate by reference the following documents that we have filed with the SEC
and any filings that we will make with the SEC in the future under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act until this offering is
terminated:
|
·
|
Annual
Report on Form 10-K for the fiscal year ended December 31,
2008;
|
|
·
|
Quarterly
Report on Form 10-Q for the fiscal quarter ended March 31,
2009;
|
|
·
|
Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30,
2009;
|
|
·
|
Current
Report on Form 8-K filed February 19,
2009;
|
|
·
|
Current
Report on Form 8-K filed February 25,
2009;
|
|
·
|
Current
Report on Form 8-K filed March 16,
2009;
|
|
·
|
Current
Report on Form 8-K filed April 13, 2009 and amended on Form 8-K/A filed
April 15, 2009;
|
|
·
|
Current
Report on Form 8-K filed May 14,
2009;
|
|
·
|
Current
Report on Form 8-K filed August 3,
2009;
|
|
·
|
Current
Report on Form 8-K filed August 13,
2009;
|
|
·
|
Current
Report on Form 8-K filed August 18,
2009;
|
|
·
|
Current
Report on Form 8-K filed September 9,
2009;
|
|
·
|
The
description of our Common Stock contained in our Form 8-A filed December
13, 2007; and
|
|
·
|
All
documents filed by us with the SEC pursuant to the Exchange Act after the
date of the initial filing of the registration statement of which this
prospectus is a part and prior to the effectiveness
thereof.
|
Copies of
these filings are available free of charge by writing to Acorn Energy, Inc., 4
West Rockland Road, Montchanin, Delaware 19710, Attention: Joe B. Cogdell, Jr.,
Secretary, or by telephoning us at (302) 656-1707. We will also provide to each
person, including any beneficial owner, to whom a prospectus is delivered, a
copy of any or all of the information that has been incorporated by reference in
the prospectus but not delivered with the prospectus. See “Where You Can Find
More Information.”
Any
statement made in this prospectus concerning the contents of any contract,
agreement or other document is only a summary of the actual document. You may
obtain a copy of any document summarized in this prospectus at no cost by
writing to or telephoning us at the address and telephone number given above.
Each statement regarding a contract, agreement or other document is qualified in
its entirety by reference to the actual document.
2,231,818
Shares of Common Stock
PROSPECTUS
SUPPLEMENT
March 8,
2010